Groupama Asset Managment Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Groupama Asset Managment lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 155.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,416 shares of the medical research company’s stock after purchasing an additional 2,079 shares during the quarter. Groupama Asset Managment’s holdings in Charles River Laboratories International were worth $627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the period. Norges Bank bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $98,886,000. Raymond James Financial Inc. purchased a new stake in Charles River Laboratories International in the fourth quarter worth approximately $42,776,000. Cooke & Bieler LP grew its position in Charles River Laboratories International by 42.1% in the 4th quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after purchasing an additional 126,372 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CRL has been the subject of several research analyst reports. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price target for the company from $190.00 to $170.00 in a research report on Friday, March 21st. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $189.77.

Charles River Laboratories International Stock Up 2.3 %

Shares of CRL opened at $149.30 on Thursday. Charles River Laboratories International, Inc. has a 12-month low of $142.76 and a 12-month high of $264.71. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $7.63 billion, a PE ratio of 995.33, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business’s 50 day moving average is $163.57 and its 200 day moving average is $181.69.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.46 earnings per share. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).